These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 35029863)

  • 1. Vortioxetine-Induced Amenorrhea: A Case Report.
    Işik M; Kurhan F; Ülkevan T; Özdemir PG
    Clin Neuropharmacol; 2022 Jan-Feb 01; 45(1):7-8. PubMed ID: 35029863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vortioxetine: A new alternative for the treatment of major depressive disorder.
    Salagre E; Grande I; Solé B; Sanchez-Moreno J; Vieta E
    Rev Psiquiatr Salud Ment (Engl Ed); 2018; 11(1):48-59. PubMed ID: 28800937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a real-world study on vortioxetine in patients with major depressive disorder in South East Asia (REVIDA).
    Chin CN; Zain A; Hemrungrojn S; Ung EK; Kwansanit P; Au Yong KC; Chong MSW; Inpa C; Yen TH; Yeoh BBD; Tay LK; Bernardo C; Lim LC; Yap CH; Fones C; Nayak A; Nelleman L
    Curr Med Res Opin; 2018 Nov; 34(11):1975-1984. PubMed ID: 29768955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study.
    Chokka P; Bougie J; Proulx J; Tvistholm AH; Ettrup A
    CNS Spectr; 2019 Dec; 24(6):616-627. PubMed ID: 30802419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder.
    Wang G; Zhao K; Reynaud-Mougin C; Loft H; Ren H; Eriksen HF; Ettrup A
    Curr Med Res Opin; 2020 May; 36(5):875-882. PubMed ID: 31990207
    [No Abstract]   [Full Text] [Related]  

  • 6. Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram.
    Levada OA; Troyan AS
    J Affect Disord; 2019 May; 250():114-122. PubMed ID: 30852363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paroxetine
    Callegari C; Ielmini M; Caselli I; Lucca G; Isella C; Diurni M; Pettenon F; Poloni N
    Psychopharmacol Bull; 2019 Feb; 49(1):28-43. PubMed ID: 30858637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
    Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
    Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence and persistence among patients with major depressive disorder enrolled in the vortioxetine tAccess Patient Support Program.
    Lawrence DF; Manjelievskaia J; Chrones L; McCue M; Touya M
    Curr Med Res Opin; 2021 Aug; 37(8):1385-1392. PubMed ID: 33904815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suicidal ideation and behavior in adults with major depressive disorder treated with vortioxetine: post hoc pooled analyses of randomized, placebo-controlled, short-term and open-label, long-term extension trials.
    Mahableshwarkar AR; Affinito J; Reines EH; Xu J; Nomikos G; Jacobsen PL
    CNS Spectr; 2020 Jun; 25(3):352-362. PubMed ID: 31199210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost per successfully treated patient for vortioxetine versus duloxetine in adults with major depressive disorder: an analysis of the complete symptoms of depression and functional outcome.
    Christensen MC; Munro V
    Curr Med Res Opin; 2018 Apr; 34(4):593-600. PubMed ID: 29235884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using early changes in cold cognition to predict response to vortioxetine in major depressive disorder.
    Park C; Zuckerman H; Subramaniapillai M; Mansur RB; Rosenblat JD; Cao B; Iacobucci M; Lee Y; Levitan R; Blumberger DM; McIntyre RS
    Psychiatry Res; 2020 Feb; 284():112767. PubMed ID: 31978627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset.
    Iovieno N; Papakostas GI; Feeney A; Fava M; Mathew SJ; Iosifescu DI; Murrough JW; Macaluso M; Hock RS; Jha MK
    J Clin Psychiatry; 2021 Jun; 82(4):. PubMed ID: 34133089
    [No Abstract]   [Full Text] [Related]  

  • 14. Canadian economic impact of improved workplace productivity in patients with major depressive disorder treated with vortioxetine.
    Lachaine J; Beauchemin C; Bibeau J; Patenaude J; Chokka P; Proulx J; Bougie J
    CNS Spectr; 2020 Jun; 25(3):372-379. PubMed ID: 31120009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vortioxetine for the treatment of depression.
    Pearce EF; Murphy JA
    Ann Pharmacother; 2014 Jun; 48(6):758-65. PubMed ID: 24676550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders.
    Christensen MC; Loft H; McIntyre RS
    J Affect Disord; 2018 Feb; 227():787-794. PubMed ID: 29689693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vortioxetine on Cognition in Schizophrenia: A Pilot Study.
    Bruno A; Zoccali RA; Troili GM; Scala L; Pandolfo G; Cedro C; Mento C; Santoro V; Spina E; Muscatello MRA
    J Clin Psychopharmacol; 2020; 40(4):381-385. PubMed ID: 32639291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applying the inclusion/exclusion criteria in placebo-controlled studies to a clinical sample: A comparison of medications.
    Zimmerman M; Balling C; Chelminski I; Dalrymple K
    J Affect Disord; 2020 Jan; 260():483-488. PubMed ID: 31539683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review of gender bias in vortioxetine clinical trials.
    Santos-Casado M; Guisado-Gil AB; Santos-Ramos B
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jun; 108():110088. PubMed ID: 32890693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Vortioxetine: a new antidepressant to treat depressive episodes].
    Colle R; Corruble E
    Encephale; 2016 Feb; 42(1):48-58. PubMed ID: 26358483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.